The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTransense Regulatory News (TRT)

Share Price Information for Transense (TRT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 94.50
Bid: 92.00
Ask: 97.00
Change: -0.50 (-0.53%)
Spread: 5.00 (5.435%)
Open: 95.00
High: 95.00
Low: 94.50
Prev. Close: 95.00
TRT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Year End Trading Update

11 Jul 2023 07:00

RNS Number : 5605F
Transense Technologies PLC
11 July 2023
 

The information contained within this announcement is deemed by the Company to constitute inside information pursuant to Article 7 of EU Regulation 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended.

 

 

11 July 2023

Transense Technologies plc

("Transense" or the "Company")

 

Year end trading update

 

Transense Technologies plc, the provider of specialist sensor technology and measurement systems, is pleased to provide a trading update for the financial year ended 30 June 2023 based on unaudited management information.

 

Highlights

· Adjusted EBITDA* for the year expected to be around £1.4m, in line with market expectations (FY22: £0.6m)

· Total revenue for the year increased by more than 35% to in excess of £3.5m, in line with market expectations (FY22: £2.6m)

o Revenues excluding iTrack royalty income ahead of management expectations, up by 41% to exceed £1.5m (FY22: £1.1m) 

o SAWsense revenue ahead of management expectations, more than doubled to £0.5m (FY22: £0.2m)

o ITrack royalty up 30% to £2.0m (FY22: £1.6m), which was lower than management expectations, but exit annual run rate exceeds £2.3m (FY22: £1.9m)

· Cash balance maintained at £1.0m, despite outgoings of £0.4m on share buyback programme and £0.2m of non-recurring reorganisation costs

o The post year end quarterly iTrack royalty receivable in July is around £0.6m

 

Revenue, Adjusted EBITDA* & Cash

 

Total revenue for the year increased by more than 35% to over £3.5m, which is in line with market expectations (FY22: £2.6m). 

 

The increase in the number of installed units generating royalty income was consistent with each of the two previous years, however, most of the growth in the current year arose in Q4 leaving the overall total iTrack royalty income for the year short of expectations. Significantly, far stronger than expected growth was generated from both SAWsense and Translogik which outweighed the royalty shortfall.

 

Adjusted EBITDA* is expected to be around £1.4m, also in line with market expectations, and more than double the prior year level (FY22: £0.6m). Profit after tax may exceed market expectations as a consequence of an increased tax credit arising from extending the recognition of deferred tax assets arising from prior years' losses.

 

Net cash balances at 30 June 2023 amounted to £1.0m (FY22: £1.0m). Trading continued to be cash generative, enabling the Company to invest a further £0.4m in the ongoing share buyback programme (FY22: £0.3m). Royalties for the final quarter of the financial year receivable at the end of July 2023 are expected to be around £0.6m, further strengthening the available cash position of the Company.

 

SAWsense

 

Revenues were more than double those of the prior year at £0.5m (FY22: £0.2m) from increased sales of motorsport equipment, combined with significant new income from customer funded feasibility and applications development projects in aerospace and automotive electric motors and drives. In addition, the Company realised income from claims under the Technology Developer Accelerator Programme ("TDAP") grant announced in May 2022 of £0.1m (FY22: £ 0.0m).

 

Business development activities have continued to generate a healthy pipeline of new incoming enquiries, and the conversion of these into chargeable feasibility and applications development projects is accelerating. Recent changes in management structure, repositioning the cost base towards customer-facing engineering and project management specialists, gave rise to non-recurring reorganisation costs of £0.2m towards the end of the financial year. It is anticipated that these changes will deliver productivity gains in future, enabling the business segment to generate sufficient income to cover its own costs more quickly.

 

Translogik

 

Revenues continued to deliver annual growth above 17% and have exceeded £1m for the first time (FY22: £0.9m). Much of this success is attributable to our market leading product range generating increased demand from established blue-chip customers, reacting to market factors such as greater call for digitisation of data and vehicle safety regulatory compliance. This leads us to believe that increased overhead investment in business development and marketing infrastructure, planned for FY24, will deliver rapid results in further acceleration of market penetration through both current and new channels to market.

 

iTrack Royalties

 

Royalty income for the financial year from iTrack in Sterling terms increased by 30% to £2.0m (FY22: £1.6m), which was below the expected growth rate of around 45%. This had been signalled during the year and was primarily due to new installations converting late in our financial year rather than uniformly, and most strongly in the final quarter. 

 

The annualised run rate of royalty income exceeded £2.3m by the end of FY23, an increase of 23% over the FY23 opening rate of £1.9m per annum.

 

Outlook and Audited Results

 

The Board is pleased with the momentum in the ongoing commercial pipeline, both for SAWsense and Translogik, which provides confidence in the prospects for the current financial year.

 

Final audited results for the year ended 30 June 2023, and a more detailed update on trading and outlook, are expected to be announced around the end of September 2023.

 

 

*Adjusted EBITDA refers to net earnings before interest, taxation, depreciation and amortisation adjusted for the cost of share based payments of £0.1m and non-recurring reorganisation costs of £0.2m.

** iTrack Royalties are based on the closing rate at 7 July 2023, however this may vary if there is a material change in rates at the end of July 2023 when the quarterly royalties are invoiced and paid.

 

 

For further information please visit www.transense.com or contact:

 

 

Transense Technologies plc

Nigel Rogers (Executive Chairman)

Melvyn Segal (CFO)

Via Walbrook PR

Allenby Capital (Nominated Adviser and Broker)

Jeremy Porter / George Payne (Corporate Finance)

Tony Quirke/Jos Pinnington (Sales and Corporate Broking)

Tel: +44 (0)20 3328 5656

Walbrook PR

Tom Cooper / Nick Rome

Tel: +44 (0)20 7933 8780

Transense@walbrookpr.com

 

 

Notes to Editors:

 

Transense is headquartered in Oxfordshire, UK and its shares are traded on AIM, a market operated by the London Stock Exchange (AIM: TRT). The Company develops and supplies advanced sensor technology and measurement solutions used by some of the world's leading companies to improve performance, efficiency and safety in demanding, mission critical applications. Transense currently operates through two active business segments:

 

· SAWsense - designs, supplies and licences advanced sensor solutions based on proven, patent protected Surface Acoustic Wave (SAW) technology to world leading companies in aerospace, electric motors and drives, industrial machinery (including robotics) and motor sport. Key customers include GE Aerospace, Parker Meggitt, McLaren Applied and several other confidential Tier One automotive and aerospace suppliers.

 

· Translogik - develops smart, connected commercial vehicle tyre inspection equipment to many of the world's leading tyre suppliers, fleet operators and service centres. That accurately measure and digitally capture safety-critical tyre condition data, used to reduce operating costs, improve safety and provide audit records for regulatory compliance. Key customers include Bridgestone, Goodyear, Continental and Prometeon (Pirelli), and leading independent providers of vehicle fleet maintenance management software.

 

Transense earns residual royalty income from iTrack - a tyre monitoring system for off-highway vehicles that was designed, developed and supplied by Translogik and sold under subscription to leading global mining companies. The associated sales, support and development infrastructure were sold to Bridgestone Corporation Japan, the world's largest tyre producer, in June 2020, and the intellectual property was licence exclusively to Bridgestone under a ten-year deal expiring in 2030.

 

For further information please contact transense@walbrookpr.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTURVNRONUBAAR
Date   Source Headline
17th Apr 20246:00 pmRNSTransaction in Own Shares & TVR
15th Apr 20242:51 pmRNSTransaction in Own Shares & TVR
28th Mar 20245:00 pmRNSTotal Voting Rights
25th Mar 20243:35 pmRNSTransaction in Own Shares & TVR
20th Mar 20249:10 amRNSRyan Maughan appointed as Managing Director
29th Feb 20245:00 pmRNSTotal Voting Rights
21st Feb 20242:40 pmRNSHolding(s) in Company
19th Feb 20247:00 amRNSInterim Results & Investor Presentation
15th Feb 20247:00 amRNSHolding(s) in Company
2nd Feb 20245:41 pmRNSTransaction in Own Shares & TVR
31st Jan 20245:00 pmRNSTotal Voting Rights
12th Jan 20247:00 amRNSDirector/PDMR Shareholding
11th Jan 20249:52 amRNSTransaction in Own Shares & TVR
8th Jan 20247:00 amRNSTranslogik Update – Appointment of Sales Director
1st Dec 20237:00 amRNSGrant of share options to Director and employee
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 202311:11 amRNSDirector/PDMR Shareholding
29th Nov 20233:01 pmRNSDirector/PDMR Shareholding
29th Nov 202310:45 amRNSResult of AGM
29th Nov 20237:00 amRNSAGM Statement & Trading Update
24th Nov 20231:11 pmRNSHolding(s) in Company
9th Nov 202312:12 pmRNSDirector/PDMR Shareholding
6th Nov 20234:48 pmRNSTransaction in Own Shares & TVR
25th Oct 202310:00 amRNSPosting of Annual Report & Notice of AGM
16th Oct 20233:23 pmRNSHolding(s) in Company
3rd Oct 20236:00 pmRNSHolding(s) in Company
28th Sep 20235:22 pmRNSHolding(s) in Company
27th Sep 20233:18 pmRNSHolding(s) in Company
26th Sep 20233:37 pmRNSDirector/PDMR Shareholding
25th Sep 202311:00 amRNSDirector/PDMR Shareholding
25th Sep 20237:00 amRNSFinal Results & Investor Presentation
22nd Sep 20239:25 amRNSHolding(s) in Company
31st Aug 20235:00 pmRNSTotal Voting Rights
29th Aug 20238:30 amRNSTransaction in Own Shares & TVR
23rd Aug 20237:00 amRNSNotice of Results & Investor Presentation
16th Aug 202310:03 amRNSHolding(s) in Company
11th Jul 20237:00 amRNSYear End Trading Update
30th Jun 20235:00 pmRNSTotal Voting Rights
22nd Jun 20234:24 pmRNSTransaction in own shares & TVR
19th Jun 20234:29 pmRNSHolding(s) in Company
16th Jun 20235:57 pmRNSTransaction in own shares & TVR
5th Jun 20237:00 amRNSSAW: Extension of scope of licence agreement
2nd Jun 20232:36 pmRNSTransaction in own shares & TVR
31st May 20235:00 pmRNSTotal Voting Rights
3rd May 20237:00 amRNSNew Automotive eDrive Business Contract
2nd May 202312:48 pmRNSAppointment of Non-Executive Director
2nd May 202310:23 amRNSTransaction in own shares & TVR
31st Mar 20235:00 pmRNSTotal Voting Rights
27th Mar 20237:00 amRNSGrant of share options to Director and employees
20th Mar 20238:49 amRNSTransaction in Own Shares & TVR

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.